Pricing Log in Create free account
Friday 6 November 2026 Export TAK’s income statement to Excel — free account

Takeda Pharmaceutical Co.

TAK Healthcare Drug Manufacturers Specialty & Generic

Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.

Revenue
+1.71%
EPS
−4.35%
Free cash flow
+54.9%
Total debt
−7.28%

Quarter to September 2026, against a year earlier

21.25 0.19 +0.90%
Market cap
$67.7B
P/E
32.0×
Fwd P/E
—
Dividend yield
1.45%
F-score
4/9
Altman Z
1.03
Beneish M
−2.65
Dividend safety
25/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Takeda Pharmaceutical Co. (TAK) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Takeda Pharmaceutical Co. (TAK) trades at a EV/EBITDA of 11.2×. Over the past ten years it has ranged from 0.0× (June 2017) to 19.2× (November 2019); the current reading is higher than 80% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2026 10.6× (11.06%)
FY2025 11.9× 6.08%
FY2024 11.2× 20.64%
FY2023 9.3× 14.20%
FY2022 8.1× 156.66%
FY2021 3.2× (77.34%)
FY2020 14.0× 86.97%
FY2019 7.5× 26.61%
FY2018 5.9× —
FY2017 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 9.4× (1.81%)
Jun 2025 9.6× (14.01%)
Jun 2024 11.1× (0.63%)
Mar 2024 11.2× 9.93%
25 more quarters

Against its own ten years

Low 0.0× High 19.2×
Ten-year median 8.9×
Current reading's percentile 80

EV/EBITDA against peers

Company EV/EBITDA
ZTS Zoetis Inc. compare 10.7×
TAK Takeda Pharmaceutical Co. 11.2×
HLN Haleon PLC Sponsored ADR compare 12.2×
VTRS Viatris Inc. compare 12.3×
UTHR United Therapeutics Corporation compare 14.7×
NBIX Neurocrine Biosciences, Inc. compare 16.5×
ELAN Elanco Animal Health Incorporated compare 19.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
TEVA Teva Pharmaceutical Industries Ltd. compare 26.2×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on TAK